Core Viewpoint - InMed Pharmaceuticals has published a peer-reviewed study demonstrating the anti-inflammatory effects of cannabinol (CBN) through modulation of the endocannabinoid system, indicating its potential therapeutic applications for inflammatory skin diseases [2][4]. Company Overview - InMed Pharmaceuticals is focused on developing proprietary small molecule drug candidates targeting CB1/CB2 receptors, with a pipeline that includes programs for Alzheimer's disease, ocular conditions, and dermatological indications [6]. Study Findings - The study, conducted in collaboration with Dr. Mauro Maccarrone, found that CBN can prevent keratinocyte inflammation via TRPV1, express mitogen-activated protein kinases, modulate endocannabinoid-regulating enzymes, increase CB1 expression, and alter cytokine release by reducing pro-inflammatory cytokines (IL-8, IL-12, IL-31) while increasing the anti-inflammatory cytokine IL-10 [3][4]. - The anti-inflammatory activity of CBN suggests its potential to regulate epidermal functions and provide protective roles in the skin [4]. Expert Commentary - Dr. Mauro Maccarrone highlighted the significance of the study in providing scientific evidence for CBN's anti-inflammatory properties, supporting its therapeutic and cosmetic applications in treating inflammatory skin conditions [4]. - Dr. Eric Hsu emphasized the importance of understanding the endocannabinoid system in the context of various diseases and how rare cannabinoids may modulate inflammation [4].

Core Viewpoint - InMed Pharmaceuticals reported positive progress in its pharmaceutical programs, particularly with its Alzheimer's treatment candidate INM-901, and announced financial results for the first quarter of fiscal 2025, highlighting a commitment to enhancing shareholder value through strategic opportunities and operational improvements [3][4]. Financial Results - For the first quarter ended September 30, 2024, InMed reported revenues of $1.3 million from its BayMedica commercial business, a 40% increase from $0.9 million in the same period last year [8]. - The company recorded a net loss of $1.68 million for the quarter, compared to a net loss of $2.54 million in the same period of the previous year, indicating an improvement in financial performance [13]. - Research and development expenses decreased to $0.8 million from $1.3 million year-over-year, primarily due to reduced spending on external contractors and patent fees [9]. - As of September 30, 2024, the company had cash and cash equivalents of $5.6 million, down from $6.6 million at the end of the previous quarter [10]. Pharmaceutical Development Programs - INM-901, targeting Alzheimer's disease, showed robust progress with positive behavioral data from long-term preclinical studies, achieving statistical significance in certain criteria [3][4]. - The drug can be administered orally, achieving therapeutic levels in the brain comparable to intraperitoneal injection, which is significant for its development [4]. - Next steps for INM-901 include further molecular analyses to characterize its mechanisms of action, with data read-out expected in calendar Q4 2024 [5]. - INM-089, aimed at treating dry Age-related Macular Degeneration (AMD), is progressing with additional in vivo preclinical studies and ongoing Chemistry, Manufacturing, and Controls (CMC) activities [6]. Corporate Actions - The company implemented a reverse stock split effective November 14, 2024, to regain compliance with Nasdaq listing requirements, reflecting its commitment to maintaining a major exchange listing [3].

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Title of each class Trading Symbol(s) Name of each exchange on which registered Common Shares, no par value INM The Nasdaq Stock Market LLC Large accelerated filer ☐ Accelerated filer ☐ Non-accelerated filer ☒ Smaller reporting company ☒ Emerging growth company ☒ FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 or ☐ TRANSITION REPORT PUR ...

● . . | --- | --- | |-------------------------------------------------------------------------------------------|-------| | | | | InMed Pharmaceuticals Files Additional Patent Application for INM-901 in the Treatment of | | | Neurodegenerative Conditions Including | | October 28, 2024 7:30 AM EDT | Source: InMed Pharmaceuticals Vancouver, British Columbia--(Newsfile Corp. - October 28, 2024) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical company focused on developing ...

InMed to Participate in Fierce Biotech Webinar on Neuroinflammation in Alzheimer's DiseaseOctober 24, 2024 8:00 AM EDT | Source: InMed PharmaceuticalsVancouver, British Columbia--(Newsfile Corp. - October 24, 2024) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates for diseases with high unmet medical needs, today announced it will be participating in the upcoming Fierce ...

InMed Appoints Dr. Barry Greenberg, Johns Hopkins University School of Medicine, to its Scientific Advisory BoardOctober 22, 2024 8:00 AM EDT | Source: InMed PharmaceuticalsVancouver, British Columbia--(Newsfile Corp. - October 22, 2024) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates for diseases with high unmet medical needs, today announced the appointment of Dr. Ba ...

. . . InMed Pharmaceuticals Reports Full Year Fiscal 2024 Financial Results and Provides Business Update September 30, 2024 8:00 AM EDT | Source: InMed Pharmaceuticals Advances INM-901 program targeting several biological pathways associated with Alzheimer's disease Further develops INM-089 demonstrating neuroprotection in the treatment of dry Age-related Macular Degeneration $4.6M revenues in fiscal year 2024, representing a 11% increase over the previous fiscal year Vancouver, British Columbia--(Newsfile ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Title of Each Class Trading Symbol Name of Each Exchange On Which Registered Common Stock, no par value INM The Nasdaq Capital Market FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-39 ...

. ● . InMed Pharmaceuticals Strengthens Patent Portfolio with Issuance of Three U.S. Patents August 21, 2024 7:30 AM EDT | Source: InMed Pharmaceuticals InMed's intellectual property portfolio totals 13 patent families covering new chemical entities, formulations, manufacturing methods and methods of use Vancouver, British Columbia--(Newsfile Corp. - August 21, 2024) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical company focused on developing a pipeline of proprietar ...

On Tuesday, InMed Pharmaceuticals Inc. INM confirmed INM-901 as an oral formulation that will be utilized in its development programs for Alzheimer's disease. Recent preclinical studies have demonstrated that INM-901, a proprietary small molecule drug candidate, can be administered orally and achieve therapeutic levels in the brain comparable to those obtained through the intraperitoneal or abdominal cavity (IP) injection, which is a common route of administration for preclinical investigation of neurodegen ...